Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells by Staab, Adrian et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Effects of HIF-1 inhibition by chetomin on hypoxia-related 
transcription and radiosensitivity in HT 1080 human fibrosarcoma 
cells
Adrian Staab*1, Jürgen Loeffler2, Harun M Said1, Désirée Diehlmann1, 
Astrid Katzer1, Melanie Beyer2, Markus Fleischer1,2, Franz Schwab1, 
Kurt Baier1, Hermann Einsele2, Michael Flentje1 and Dirk Vordermark1
Address: 1Department of Radiation Oncology, University of Würzburg, 97080 Würzburg, Germany and 2Medical Clinic II, University of Würzburg, 
97080 Würzburg, Germany
Email: Adrian Staab* - staab_a@klinik.uni-wuerzburg.de; Jürgen Loeffler - loeffler_j@klinik.uni-wuerzburg.de; 
Harun M Said - said_h@klinik.uni-wuerzburg.de; Désirée Diehlmann - La.Reine@gmx.net; Astrid Katzer - labor@strahlentherapie.uni-
wuerzburg.de; Melanie Beyer - beyer_m@klinik.uni-wuerzburg.de; Markus Fleischer - markus.fleischer@mac.com; 
Franz Schwab - schwab_f@klinik.uni-wuerzburg.de; Kurt Baier - Baier_K@klinik.uni-wuerzburg.de; Hermann Einsele - einsele_h@klinik.uni-
wuerzburg.de; Michael Flentje - flentje_m@klinik.uni-wuerzburg.de; Dirk Vordermark - vordermark_d@klinik.uni-wuerzburg.de
* Corresponding author    
Abstract
Background:  Hypoxia-inducible factor-1 (HIF-1) overexpression has been linked to tumor
progression and poor prognosis. We investigated whether targeting of HIF-1 using chetomin, a
disrupter of the interaction of HIF-1 with the transcriptional coactivator p300, influences the
radiosensitivity of hypoxic HT 1080 human fibrosarcoma cells.
Methods: Optimal dose of chetomin was determined by EGFP-HRE gene reporter assay in stably
transfected HT 1080 cells. Cells were assayed for expression of the hypoxia-inducible genes
carbonic anhydrase 9 (CA9) and vascular endothelial growth factor (VEGF) by RT-PCR and for
clonogenic survival after irradiation with 2, 5 or 10 Gy, under normoxic or hypoxic (0.1% O2, 12
h) conditions in the presence or absence of chetomin (150 nM, 12 h, pre-treatment of 4 h).
Results: Chetomin treatment significantly reduced CA9 and VEGF mRNA expression in hypoxic
cells to 44.4 ± 7.2% and 39.6 ± 16.0%, respectively, of untreated hypoxic controls. Chetomin clearly
reduced the modified oxygen enhancement ratio (OER') compared to untreated cells, from 2.02
to 1.27, from 1.86 to 1.22 and from 1.49 to 1.06 at the 50%, 37% and 10% clonogenic survival levels,
respectively.
Conclusion: HIF-1 inhibition by chetomin effectively reduces hypoxia-dependent transcription
and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro.
Background
Hypoxia in solid tumors is associated with changes in
gene expression, mRNA translation and poor prognosis in
many tumour entities [1-3]. Furthermore hypoxia
enhances radioresistance in tumors and mediates resist-
ance to chemotherapy [4,5]. Hypoxia-inducible factor-1
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(HIF-1) is a central regulator of transcriptional response
of mammalian cells to oxygen deprivation [6,7].
It has been shown that HIF-1 is associated with poor out-
come for multiple cancer types and high HIF-1 expression
is a predictor of poor prognosis after radiotherapy [8-11].
Therefore hypoxia inducible factor-1 (HIF-1) has been
identified as a potential target to overcome hypoxia
induced radioresistance [12].
Kung et al. [13] identified chetomin as a small molecule
blocking the HIF pathway. Chetomin disrupts the struc-
ture of the CH1 domain of p300, a transcriptional coacti-
vator, thereby precluding its interaction with HIF and
attenuating hypoxia-inducible transcription. The aim of
the present study was to investigate if HIF-1 inhibition by
chetomin affects hypoxia-induced radioresistance in
human tumor cells.
Methods
Cell culture
Early-passage HT 1080 human fibrosarcoma cells from
the American Type Culture Collection (ATCC, Rockville,
MD) were maintained under standard conditions as pre-
viously described [14]. Cells were cultured in MEM sup-
plemented with 10% fetal bovine serum and 100,000 U/
L penicillin and 100 mg/L streptomycin (all from Sigma,
St. Louis, MO, USA) with 5% CO2 in a well-humidified
incubator. For hypoxia experiments, early-passage cells
were split and seeded into 80-mm glass Petri dishes at 2 ×
106 cells per dish. On the following day, when cells were
still exponentially growing, cells were transferred without
further medium change to a Ruskinn (Cincinnati, OH,
USA) Invivo2 hypoxic workstation for hypoxia treatment.
The oxygen concentration of 0.1% was achieved inside the
workstation before transfer of the cells by calibrating the
oxygen probe against air according to the manufacturer's
instructions; adjusting the instrument settings to the
desired O2 concentration, 5% CO2 and 37°C; and subse-
quent flooding of the chamber with an appropriate gas
mixture of pressurized air, N2, and CO2 through an auto-
mated gas mixing module.
Aerobic conditions were maintained in the incubator at
5% CO2 and 20% O2. Where indicated chetomin (Alexis
Biochemicals, San Diego, CA, USA), a pharmacological
inhibitor of HIF was used. Different concentrations and
(pre-) incubation times of chetomin were assayed in pilot
FACS experiments. In RT-PCR and clonogenic survival
experiments, chetomin was added in a concentration of
150 nM to fully supplemented medium four hours before
treatment with hypoxia. HT 1080 cells were then trans-
ferred to the hypoxic workstation (0.1% O2, 12 h) or to
the well-humidified incubator (12 hours) without chang-
ing medium. HT1080 cells were thus treated for 16 hours
with chetomin (150 nM) prior to radiation treatment.
Flow cytometry of 5HRE-hCMVmp-EGFP HT1080 cells
To study the effect of chetomin on hypoxia-responsive
element (HRE) binding of HIF-1 and gene transactivation,
we used HT 1080 cells stably transfected with enhanced
green fluorescent protein (EGFP) under the control of a
hypoxia-responsive promoter containing five copies of a
hypoxia-responsive element from the human vascular
endothelial growth factor (VEGF) gene. HT 1080 cells
transfected with the same EGFP under the control of a
strong constitutive, hypoxia-independent CMV promoter
were used as positive controls as described previously
(both cell types kindly provided by J.M. Brown, Stanford
University, USA) [14]. The design of the constructs and
their application as a reporter system of tumor hypoxia
has been previously reported [15].
Cells were exposed to experimental conditions as for PCR
experiments in glass Petri dishes. Due to the known
requirement of sufficient reoxygenation for the develop-
ment of hypoxia-dependent, HRE-mediated EGFP fluo-
rescence [14], all samples were returned to aerobic
conditions in the incubator for 4 h before FACS analysis
as previously described [14]. EGFP fluorescence was meas-
ured on a FacsCalibur flow cytometer (Becton Dickinson)
as described previously [14]. Dead cells and debris were
gated out on the basis of forward and side scatter dot
plots.
RT-PCR
Quantitative real-time RT-PCR assay was performed using
the LightCycler instrument and the Fast Start Master
Hybridization detection system (both from Roche Diag-
nostics, Mannheim, Germany) to quantify the mRNA
expression of VEGF and CA9. Directly following the
hypoxia/chetomin (or respective control) treatment
(without reoxygenation), total RNA was purified from 106
HT 1080 cells using RNeasy Mini kit (Qiagen, Hilden,
Germany) according to the manufacturer's instructions.
First-strand cDNA was synthesized from 900 ng total RNA
with use of Quantitect Reverse Trancriptase Kit (Qiagen)
according to the protocol of the manufacturer. For the
amplicon detection, the Fast Start Master Hybridization
detection system (Roche Diagnostics) was used taking
0,25 µM (each) of the VEGF- (5'-cctttccctttcctcgaact, 5'-
cagaatcatcacgaagtggtgaa) and CA9-specific primers (5'-
ttccaatatgaggggtctct 5'-ttcagctgtagccgagagt). Specific
probes were either labelled with FAM-TAMRA (6FAM-cta-
caccgccctgtgcccac-TMR for quantification of CA9) or LC-
Red640 (5'-aagctcatctctcctatgtgctggcct-FL, 5'-LC Red640-
ggtgaggtttgatccgcataatctgc-PH, for quantification of
VEGF). The following parameters were used: VEGF: 95°CBMC Cancer 2007, 7:213 http://www.biomedcentral.com/1471-2407/7/213
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for 600 s: 95°C for 9 s, 55°C for 15 s, 72°C for 20 s and
40°C for 30 s. Forty-five cycles were performed. CA9:
95°C for 600 s: 95°C for 9 s, 60°C for 15 s, 72°C for 20 s
and 40°C for 30 s. Forty-five cycles were performed.
Radiation treatment and clonogenic assay
Immediately after the 12-hour hypoxia treatment or con-
trol treatment (± chetomin 150 nM), the glass culture
dishes were enclosed in Perspex shells inside the hypoxic
workstation and transferred to the linear accelerator. Cells
were irradiated with a dose of 2, 5 or 10 Gy (dose rate 2.5
Gy/min, 6 MV photons, room temperature, adequate Per-
spex bolus). Aerobic cells were irradiated in similar Per-
spex shells with holes permitting unimpaired air
exchange.
Cell survival was quantified by standardized colony-form-
ing assay [16]. HT 1080 cells from untreated or irradiated
monolayers were trypsinized and resuspended immedi-
ately after treatment, seeded in culture flasks at appropri-
ate dilutions. On day 14, cells were stained with crystal
violet, and colonies consisting of at least 50 cells were
counted. The plating efficiency (PE) was expressed as the
percentage of colonies relative to the number of cells
seeded. The ratio of PE of irradiated and respective control
cells, correcting for differences in plating efficiency of
unirradiated cells, gave the relative survival (S). Survival
curves were generated by plotting S as a function of radia-
tion dose (D).
The survival data were fitted with the linear-quadratic
model: S(D) = exp [-(αD + βD2)] by optimizing variable
parameters α and β [17]. A modified oxygen enhance-
ment ratio (OER') was calculated as the ratio of the doses
to achieve the same survival at 0.1% O2 as at ambient oxy-
gen tensions: OER' = Dhypoxia/Dnormoxia. OER' was
obtained at cell survival levels of 50%, 37% and 10%.
Statistical analysis
Expression levels of mRNA and clonogenic survival were
compared between treatment groups by Mann-Whitney U
test using Statistica vs. 6.1 (Statsoft, Tulsa, OK, USA) soft-
ware (p < 0.05 considered significant).
Results
Effects of chetomin on HIF-1-dependent transcriptional 
activation
In HT 1080 cells stably transfected with a construct of
EGFP under the control of a hypoxia-responsive 5HRE-
hCMVmp promoter, the addition of chetomin markedly
suppressed the hypoxic increase in EGFP fluorescence sig-
nal (Figure 1). This suppression of EGFP fluorescence sig-
nal was dose and incubation-time dependent (Figure 2).
A maximum suppression of EGFP fluorescence signal was
measured when chetomin was added four hours prior
hypoxia treatment (0.1% O2, 12 h) and in a final concen-
tration of 150 nM. Higher doses of chetomin led to an
increasing proportion of completely EGFP-negative cells
indicating substantial cytotoxicity (data not shown).
Chetomin had no effect on HRE-independent EGFP fluo-
rescence as shown by comparable fluorescence in
chetomin-treated (150 nM) and control HT 1080 cells
transfected with the constitutive CMV promoter (Figure
1).
Effects of chetomin on VEGF and CA9 mRNA expression
Under hypoxic conditions, the treatment of HT 1080 cells
with chetomin (150 nM) resulted in a significantly
reduced hypoxic VEGF and CA9 mRNA expression (p <
0.05; Figure 3). The mean hypoxic VEGF mRNA expres-
sion was reduced to 39.6 ± 16.0% of the hypoxic control
(100%) and the mean CA9 mRNA expression was reduced
to 44.4 ± 7.2% of the hypoxic control.
Clonogenic survival
Treatment with chetomin (150 nM) alone significantly
reduced the plating efficiency under normoxic conditions
from 76.2 ± 8.9% (mean ± SEM) to 46.0 ± 5.8% (p < 0.05)
and under hypoxic conditions from 71.7 ± 7.3% to 28.6 ±
3.8% (p < 0.05) (Figure 4).
Chetomin enhanced radiation treatment efficacy under
severely hypoxic conditions (Figure 5). In the absence of
chetomin, survival was significantly increased under
hypoxic conditions compared to normoxia (p < 0.05). In
chetomin-treated cells, survival under hypoxia was signif-
icantly increased, compared to normoxia (chetomin) only
at the 10 Gy dose level. OER was calculated at 50%, 37%
and 10% survival levels obtained from calculated α and β
values. Incubation with chetomin reduced the OER' after
radiation at all survival levels (Table 1).
Discussion
HIF-1 inhibition has been shown to slow tumor growth in
in-vitro and in-vivo tumor models [13,18] and to act syner-
gistically with other treatment modalities such as radio-
therapy [19]. We now show in a human fibrosarcoma cell
line that HIF-1 targeting with chetomin (150 nM) sup-
presses the transcriptional response to hypoxia and
reduces hypoxic radioresistance in vitro. This is, to our
knowledge, the first report of increased radiosensitivity of
hypoxic cells in vitro in response to chetomin.
Experimental conditions now chosen were based on our
previous observation that a near-maximal HIF-1α expres-
sion occurs at 12 h of hypoxia at an oxygen concentration
of 0.1% O2, which represents a level of hypoxia that is fre-
quently observed in solid tumors and radiobiologically
relevant [20]. At the dose level of 150 nM, chetomin
exhibited a maximum specific effect on HRE-regulatedBMC Cancer 2007, 7:213 http://www.biomedcentral.com/1471-2407/7/213
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EGFP fluorescence whereas higher doses did not further
suppress HRE activation. This dose level was higher than
the 50 nM described as effectively suppressing HIF-1 func-
tion in Hep 3B cells in vitro but lower than the peak tumor
concentration in xenograft tumors of 300 nM [13]. In the
clonogenic assay, chetomin 150 nM had a cytotoxic effect
in aerobic and, in particular, in hypoxic HT 1080 cells.
Correcting for this effect, chetomin 150 nM effectively
radiosensitized hypoxic HT 1080 cells whereas the radio-
sensitivity of normoxic cells was unaltered. The effect on
normoxic cells could be related to the suppression of basal
HIF-1 function which is present in HT 1080 cells under
normoxia as suggested by the previously described basal
fluorescence of EGFP under control of the hypoxia-
responsive promoter [14].
Williams et al. could demonstrate an enhanced response
to radiotherapy in tumours deficient in the function of
hypoxia-inducible factor-1 [21]. HIF-1α antisense treat-
ment suppressed HIF-1α expression by up to 80% under
both normoxic and hypoxic conditions and resulted in
significant resistance of U87 malignant glioma cells to the
cytotoxicity of cisplatin, etoposide, and vincristine [22].
Sasabe et al. demonstrated that down-regulation of HIF-
Chetomin (CHT) inhibits the hypoxic activation of hypoxia- responsive-element-(HRE-) mediated EGFP fluorescence in  stably transfected HT 1080 human fibrosarcoma cells in a  dose and incubation-time dependent manner Figure 2
Chetomin (CHT) inhibits the hypoxic activation of hypoxia-
responsive-element-(HRE-) mediated EGFP fluorescence in 
stably transfected HT 1080 human fibrosarcoma cells in a 
dose and incubation-time dependent manner. After chetomin 
pre-treatment for two or four hours, HT 1080 cells were 
cultured for 12 hours under hypoxia resulting in total 
chetomin treatment times of 14 or 16 h as indicated. A max-
imum suppression of EGFP fluorescence was achieved when 
cells were treated with 150 nM chetomin for 16 hours (rep-
resentative FACS experiment). Higher doses had no addi-
tional effect.
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Effect of chetomin on the fluorescence of EGFP under the 
control of a hypoxia-responsive promoter containing five 
copies of a hypoxia-responsive element (5HRE) or under the 
control of a hypoxia-independent constitutive CMV pro-
moter (CMV) in stably transfected HT 1080 human fibrosar-
coma cells. Cells were treated in air (20% O2) or hypoxia 
(0.1% O2). Black line indicates treatment with chetomin 150 
nM, grey shaded area fluorescence of control cells. Chetomin 
has no effect on EGFP fluorescence in CMV cells, but 
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orescence in 5HRE cells.
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1α expression by small interfering RNA enhances the sus-
ceptibility of oral squamous cell carcinoma cells to
chemo- and radiotherapy [23]. Pore et al. [24] showed
that decreases of both VEGF and HIF-1α expression result
in radiosensitization in vivo and in vitro.
In contrast to results of the present study, Arvold et al. [25]
showed that in mouse embryonic fibroblasts hypoxia-
mediated radiation resistance is independent of HIF-1α.
Furthermore, Moeller at al. detected that radiation acti-
vates HIF through reoxygenation-induced stabilization of
HIF-1 dimer through free radical intermediates and reox-
ygenation-mediated depolymerization of hypoxia-
induced translational suppressors known as stress gran-
ules [26].
Published results and our data suggest that HIF is an
attractive target to overcome hypoxia-induced radioresist-
ence. Kung et al. [13] could demonstrate in vitro and in
vivo that administration of chetomin inhibited hypoxia-
inducible transcription within tumors and inhibited
Clonogenic survival of HT1080 human fibrosarcoma cells  after radiation treatment in air (20% O2) or hypoxia (0.1%  O2): HT1080 cells were cultured for 12 hours under  hypoxia/normoxia and in the presence or absence of 150 nM  Chetomin (CHT) Figure 5
Clonogenic survival of HT1080 human fibrosarcoma cells 
after radiation treatment in air (20% O2) or hypoxia (0.1% 
O2): HT1080 cells were cultured for 12 hours under 
hypoxia/normoxia and in the presence or absence of 150 nM 
Chetomin (CHT). Chetomin was added four hours prior to 
hypoxia (n = 3, mean ± sem). Chetomin 150 nM has no effect 
on the radiosensitivity of HT 1080 cells in air, but increases 
radiosensitivity under hypoxic conditions.
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Inhibition of VEGF (A) and CA9 (B) mRNA expression under 
hypoxia: HT 1080 human fibrosarcoma cells were pre-
treated with 150 nM chetomin (CHT) for four hours and 
transferred for 12 h to hypoxic (0.1% O2) or maintained in 
aerobic (20% O2) conditions. Quantitative real-time RT-PCR 
was performed to quantify the expression of VEGF or CA9 
mRNA (n = 3, mean ± sem). Incubation with CHT caused a 
reduced hypoxic expression of CA9 and VEGF mRNA (* 
indicates significant difference from hypoxic control, p < 
0.05).
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tumor growth, thereby establishing the feasibility of dis-
rupting a signal transduction pathway by targeting the
function of a transcriptional coactivator with a small mol-
ecule in vivo. In the present study, mechanistic experi-
ments focussing on the mode of HIF-1 inhibition by
chetomin, in particular its interaction with p300, as pre-
sented by Kung et al. [13] were not performed. The find-
ings now presented are limited to one in-vitro model and
one HIF-1 targeting agent. The selection of clinically
promising HIF-1 targeting agents will require a broader
screen of several substances in a panel of cell lines in vitro
with confirmation of results in experimental in-vivo mod-
els. Recent studies suggest that the success of HIF-1 inhibi-
tion in vivo may critically depend on other factors of the
tumor microenvironment such as glucose metabolism
and pH [27,28] and on the ability of any given strategy to
eliminate virtually all HIF-1 function as cell mixing exper-
iments described by Williams et al. [21] indicated that 1%
of cells with intact HIF-1 function within a tumor are suf-
ficient to preserve tumor growth.
In conclusion, we could demonstrate that HIF-1 inhibi-
tion with chetomin downregulates the expression of HIF-
1-regulated genes (CA9, VEGF) and enhances radiation
response under severely hypoxic conditions in human HT
1080 cells. Further studies must show whether selective
inhibition of HIF-1 will increase radiosensitivity in vivo.
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